We value your privacy

We use cookies to improve your browsing experience, provide personalised content, and analyse our traffic. By clicking "Accept All," you agree to our use of cookies. You can manage your preferences or learn more by clicking "Customise".

Customise Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorised as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site.... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

Advertisement cookies are used to provide visitors with customised advertisements based on the pages you visited previously and to analyse the effectiveness of the ad campaigns.

Other cookies are those that are being identified and have not been classified into any category as yet.

Partners » Our Stories » I am part of the DTG story

I am part of the DTG story

I am part of the DTG story

Please accept cookies to access this content

Since the signing of licensing agreements between ViiV Healthcare and MPP, with the support of Unitaid and numerous public health partners, over 1 billion packs of generic DTG have been distributed to 24 million adults and children living with HIV in 128 low- and middle-income countries. This has resulted in over 90% of individuals on antiretroviral treatment in these countries receiving DTG-based regimens.

In preparation of the 10 year anniversary of the DTG licence which occurred in April 2024, MPP has met with communities taking generic DTG regimens or working with people who do. Our film is a collection of testimonials on the impact of DTG on lives, but also personal accounts of living with HIV.

Here are their stories:

Access to dolutegravir, Senegal

Please accept cookies to access this content

Discover the transformative impact of dolutegravir in Senegal. In November 2023, we visited BOKK YAKAAR, an NGO dedicated to supporting individuals living with HIV in Fatick. Our journey allowed us to gather firsthand feedback on the rollout of dolutegravir for both adults and children. Through interviews with healthcare workers, the director of BOKK YAKAAR, Ibrahima Ba, and the people directly affected by HIV, this video offers a compelling look at the real-world benefits and challenges of improving access to essential HIV treatments.

HIV is alive, South Africa

Please accept cookies to access this content


Join Nombeko Mpongo, a resilient individual living with HIV in South Africa, as she shares her inspiring journey towards better health. In this testimonial, Nombeko discusses the life-altering access to HIV treatment and the profound difference dolutegravir has made in her life. She also touch on the next challenges to end the HIV epidemic. Her story is one of hope and empowerment.

HIV is alive in men, South Africa

Please accept cookies to access this content

Welcome to an essential dialogue on the journey of HIV access and treatment for men in South Africa. Historically, the focus and funding have been directed towards women, leaving a critical gap in the conversation and care on men. Dr. Katherine Gill from the Desmond Tutu Health Foundation, provides her expert perspective on why a differentiated approach is crucial for diagnosing and treating men. Alongside Dr. Gill’s insights, we hear a powerful testimonial from a man who will share his personal story from diagnosis to present day.

Transforming Lives with Paediatric HIV Care

Please accept cookies to access this content

Published on the occasion of World Children’s Day 2024, this video provides an overview of The Nyumbani Children’s Home in Kenya, which supports babies and children with HIV. Nyumbani, meaning “home” in Kiswahili, has evolved from a hospice into a residence for approximately 100 orphans and vulnerable children. The video discusses advancements in paediatric HIV medicines and the upcoming rollout of paediatric ALD, a fixed-dose combination for children living with HIV. It highlights the impact of access to adapted paediatric formulations in LMICs and the efforts of MPP and its partners in these initiatives.

Share page:
Facebook
Linkedin
Bluesky

Contact Us

Press and Media

About Us

The Medicines Patent Pool (MPP) is a United Nations-backed public health organisation working to increase access to and facilitate the development of life-saving medicines for low- and middle-income countries. Through its innovative business model, MPP partners with civil society, governments, international organisations, industry, patient groups, and other stakeholders to prioritise and license needed medicines and pool intellectual property to encourage generic manufacture and the development of new formulations.

To date, MPP has signed agreements with 22 patent holders for 13 HIV antiretrovirals, one HIV technology platform, three hepatitis C direct-acting antivirals, a tuberculosis treatment, a cancer treatment, four long-acting technologies, a post-partum haemorrhage medicine, three oral antiviral treatments for COVID-19 and 16 COVID-19 technologies.

MPP was founded by Unitaid, which continues to be MPP’s main funder. MPP’s work on access to essential medicines is also funded by the Swiss Agency for Development and Cooperation (SDC), Government of Canada, the World Intellectual Property Organization (WIPO) and the Government of Flanders. MPP’s activities in COVID-19 are undertaken with the financial support of the Japanese Government, the French Ministry for Europe and Foreign Affairs, the German Agency for International Cooperation, and SDC.

MPP Logo

Subscribe to our Newsletter

About Us
Licences
MedsPaL
Careers & RFPs
Contact

Founded & funded by

Unitaid Logo

Other funders